Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $196 | $210 | $187 | $186 |
| - Cash | $11 | $13 | $8 | $12 |
| + Debt | $31 | $26 | $28 | $31 |
| Enterprise Value | $216 | $223 | $208 | $204 |
| Revenue | $52 | $47 | $43 | $44 |
| % Growth | 10.8% | 7.4% | -1.2% | – |
| Gross Profit | $39 | $34 | $32 | $32 |
| % Margin | 75.2% | 73.3% | 73.4% | 73.3% |
| EBITDA | $21 | $18 | $15 | $31 |
| % Margin | 40.1% | 39.1% | 33.8% | 70.3% |
| Net Income | $12 | $15 | $7 | $24 |
| % Margin | 23.1% | 31.8% | 16% | 54.6% |
| EPS Diluted | 5.87 | 7.1 | 3.17 | 10.63 |
| % Growth | -17.3% | 124% | -70.2% | – |
| Operating Cash Flow | $18 | $14 | $14 | $15 |
| Capital Expenditures | -$4 | -$3 | -$2 | -$3 |
| Free Cash Flow | $14 | $12 | $12 | $13 |